Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2021-07-26 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and types of meetings. There is no financial data, report content, or detailed presentation included. The document is an announcement about upcoming investor meetings rather than the meetings' content or a report. Therefore, it fits best under Investor Presentation (IP) as it relates to investor communications and meetings, but since it only announces the schedule and does not contain a presentation itself, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory disclosure about investor meetings without substantive financial or presentation content. The document length is short and it is an announcement, not a report or transcript.
2021-07-26 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement for the company's unaudited financial results for Q1 FY 2022. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which mandates disclosure of financial results via advertisements. The document itself is not the financial report but an announcement about the advertisement of the unaudited quarterly results. The document length is short (1616 characters), and it states that the advertisement is enclosed for information and records. Therefore, this is not the Interim/Quarterly Report itself but a Regulatory Filing announcing the publication of financial results in newspapers.
2021-07-22 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is a Monitoring Agency Report for the quarter ended June 30, 2021, issued by Axis Bank Limited for Gland Pharma Limited. It references SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and details the utilization of IPO proceeds, including itemized costs, progress on objectives, and deployment of unutilized proceeds. The report is a regulatory compliance document monitoring the use of funds raised through an IPO, not a full annual or quarterly financial report. It is not an announcement of a report but the report itself, containing substantive financial and compliance data related to capital utilization. This fits the category of a Capital/Financing Update (CAP) as it relates to monitoring the use of capital raised and compliance with capital raising regulations.
2021-07-21 English
Investor Presentation
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Financial Results Q1’FY22' and dated 21st July 2021, indicating it covers quarterly financial performance. It contains detailed financial data such as revenue, EBITDA, PBT, PAT, margins, balance sheet items, cash flow, and segment revenue breakdowns. The content includes comprehensive financial highlights, operational metrics, and business outlook for the quarter ending Q1 FY22. There is no indication that this is merely an announcement or a presentation; rather, it contains substantive financial data and analysis for a quarterly period. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-07-21 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing Gland Pharma's financial results for the first quarter ended June 30, 2021 (Q1FY22). It contains detailed financial data such as revenue, EBITDA, PAT, market-wise revenue breakdown, R&D expenses, and capex for the quarter. It also mentions an upcoming earnings call to discuss these results. The presence of comprehensive quarterly financial figures and analysis indicates this is a quarterly financial report rather than just an earnings release (which typically contains only key highlights). The document length (8434 characters) and detailed financial tables support this classification. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q1 2022
2021-07-21 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Gland Pharma Limited dated July 21, 2021, reporting the outcome of a Board Meeting. It includes the approval of unaudited financial results for the quarter ended June 30, 2021, along with a Limited Review Report by the auditors. The document contains extensive financial data such as income, expenses, profit before tax, tax expenses, and profit for the period, all for the quarter ended June 30, 2021. It also includes auditor's review comments and detailed financial tables. The presence of unaudited quarterly financial results with substantive financial data and analysis indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report or a certification letter but contains the actual financial results and auditor's review. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2021-07-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.